> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# NIH Ends Lilly Covid Antibody Study
- URL: https://www.fdaweb.com/nih-ends-lilly-covid-antibody-study/
- Published: 2020-10-27T12:00:00.000Z
- Updated: 2026-09-14T16:34:11.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5147962

Following the advice from an independent data and safety monitoring board, the National Institutes of Health (NIH) says no additional subjects will be enrolled in a clinical trial evaluating a Lilly investigational monoclonal antibody in hospitalized patients with Covid-19\. The board made its recommendation based on a low likelihood that the intervention would be of clinical value in this hospitalized patient population, an NIH [statement](https://www.niaid.nih.gov/news-events/statement-nih-sponsored-activ-3-trial-closes-ly-cov555-sub-study?ref=fdaweb.com) says.

NIH says the 326 participants already enrolled in the study will continue to be followed until day 90\. Study participants received either an experimental agent or a matched placebo and also received standard of care for patients hospitalized with Covid-19 including the antiviral remdesivir.